October 15, 2004Journal of Cutaneous Pathology

Evaluation of anti‐thrombomodulin antibody as a tumor marker for vascular neoplasms

View Full Paper

Ask AI

Bookmark

Why the study?

Is anti-thrombomodulin antibody a sensitive marker for vascular neoplasms compared to established endothelial markers?

Population

71 vascular neoplasms

Comparison

Immunostaining with anti-thrombomodulin antibody vs Immunostaining with anti-CD34 antibody and von…

Design

Cross-sectional

Authors

TMTrey ManningArkansas Cardiology BSBruce R. SmollerUniversity of Rochester THThomas HornHarvard University

Discussion

Member takes

Implication

Anti-TM may complement CD34 in vascular neoplasm IHC; leaves open specificity advantages in diagnostic pathology.

Structured PICO

Is anti-thrombomodulin antibody a sensitive marker for vascular neoplasms compared to established endothelial markers?

Population

71 vascular neoplasms (30 capillary hemangiomas, 10 pyogenic granulomas, 5 tufted angiomas, 17 Kaposi's sarcomas, and 9 angiosarcomas)

Intervention

Immunostaining with anti-thrombomodulin (anti-TM) antibody

Comparator

Immunostaining with anti-CD34 antibody and von Willebrand factor (vWF)

Outcome

Immunostaining sensitivity and intensitysurrogate

Anti-thrombomodulin antibody is a sensitive marker for vascular neoplasms, though slightly less sensitive than anti-CD34, it may offer specificity advantages.

Cite This Study

Manning et al. (2004) studied this question.

synapsesocial.com/papers/6a840358833903f64df2ed6d https://doi.org/10.1111/j.0303-6987.2004.00245.x

View Full Paper

Ask AI

Bookmark

Evaluation of anti‐thrombomodulin antibody as a tumor marker for vascular neoplasms

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Evaluation of anti‐thrombomodulin antibody as a tumor marker for vascular neoplasms

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider